These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 25371057)

  • 1. Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy.
    Cancarini A; Costagliola C; Dell'omo R; Romano M; Morescalchi F; Agnifili L; Ruggeri G; Semeraro F
    Minerva Endocrinol; 2014 Dec; 39(4):305-11. PubMed ID: 25371057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy.
    Semeraro F; Cancarini A; Morescalchi F; Romano MR; dell'Omo R; Ruggeri G; Agnifili L; Costagliola C
    Diabetes Metab; 2014 Dec; 40(6):445-51. PubMed ID: 24878492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aqueous humour levels of vascular endothelial growth factor and erythropoietin in patients with diabetic macular oedema before and after intravitreal erythropoietin injection.
    Lim JW; Han JR
    Clin Exp Ophthalmol; 2011 Aug; 39(6):537-44. PubMed ID: 21819507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
    Ma Y; Zhang Y; Zhao T; Jiang YR
    Am J Ophthalmol; 2012 Feb; 153(2):307-313.e2. PubMed ID: 21982107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.
    Matsumoto M; Suzuma K; Maki T; Kinoshita H; Tsuiki E; Fujikawa A; Kitaoka T
    Am J Ophthalmol; 2012 May; 153(5):896-902.e1. PubMed ID: 22265145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
    Qian J; Lu Q; Tao Y; Jiang YR
    Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy.
    Suzuki Y; Suzuki K; Yokoi Y; Miyagawa Y; Metoki T; Nakazawa M
    Retina; 2014 Jan; 34(1):165-71. PubMed ID: 23851630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection.
    Costagliola C; Daniele A; dell'Omo R; Romano MR; Aceto F; Agnifili L; Semeraro F; Porcellini A
    Exp Eye Res; 2013 May; 110():50-4. PubMed ID: 23454098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
    Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
    Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy.
    Sawada O; Kawamura H; Kakinoki M; Sawada T; Ohji M
    Arch Ophthalmol; 2007 Oct; 125(10):1363-6. PubMed ID: 17923544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab.
    Zhou M; Chen S; Wang W; Huang W; Cheng B; Ding X; Zhang X
    Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):3874-9. PubMed ID: 23674760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFβ1 in diabetic eyes undergoing vitrectomy.
    Loukovaara S; Robciuc A; Holopainen JM; Lehti K; Pessi T; Liinamaa J; Kukkonen KT; Jauhiainen M; Koli K; Keski-Oja J; Immonen I
    Acta Ophthalmol; 2013 Sep; 91(6):531-9. PubMed ID: 23106921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low intravitreal angiopoietin-2 and VEGF levels in vitrectomized diabetic patients with simvastatin treatment.
    Tuuminen R; Sahanne S; Loukovaara S
    Acta Ophthalmol; 2014 Nov; 92(7):675-81. PubMed ID: 24506800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles.
    Patel JI; Tombran-Tink J; Hykin PG; Gregor ZJ; Cree IA
    Exp Eye Res; 2006 May; 82(5):798-806. PubMed ID: 16324700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy.
    Mohan N; Monickaraj F; Balasubramanyam M; Rema M; Mohan V
    J Diabetes Complications; 2012; 26(5):435-41. PubMed ID: 22699109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy.
    Citirik M; Kabatas EU; Batman C; Akin KO; Kabatas N
    Ophthalmic Res; 2012; 47(1):7-12. PubMed ID: 21691136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy.
    Wakabayashi Y; Usui Y; Okunuki Y; Ueda S; Kimura K; Muramatsu D; Kezuka T; Goto H
    Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6403-10. PubMed ID: 22899753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
    Itakura H; Kishi S; Kotajima N; Murakami M
    Ophthalmology; 2004 Oct; 111(10):1880-4. PubMed ID: 15465550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Erythropoietin concentrations in the vitreous body from patients with proliferative diabetic retinopathy].
    Asensio-Sánchez VM; Gómez-Ramírez V; Morales-Gómez I
    Arch Soc Esp Oftalmol; 2008 Mar; 83(3):169-72. PubMed ID: 18311675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of before versus after intravitreal bevacizumab injection, growth factor levels and fibrotic markers in vitreous samples from patients with proliferative diabetic retinopathy.
    Ozer F; Tokuc EO; Albayrak MGB; Akpinar G; Kasap M; Karabas VL
    Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1899-1906. PubMed ID: 35028761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.